Viridian Therapeutics Inc (VRDN) — Cash Flow-to-Debt Ratio
Viridian Therapeutics Inc (VRDN) has a Cash Flow-to-Debt Ratio of -0.78x as of March 2026, meaning its operating cash flow of $-119.65 Million could theoretically repay -1% of its total liabilities ($153.01 Million) in one year. See Viridian Therapeutics Inc (VRDN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Viridian Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Viridian Therapeutics Inc across 14 annual periods. Also explore net asset momentum of Viridian Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Viridian Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Viridian Therapeutics Inc. For market capitalisation and broader financial context, see VRDN stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.56x | $-276.39 Million | $177.25 Million | ▲ +52.5% |
| 2024 | -3.28x | $-232.32 Million | $70.76 Million | ▲ +13.7% |
| 2023 | -3.81x | $-184.17 Million | $48.40 Million | ▼ -62.3% |
| 2022 | -2.34x | $-93.84 Million | $40.03 Million | ▲ +31.3% |
| 2021 | -3.41x | $-54.58 Million | $15.99 Million | ▼ -28.6% |
| 2020 | -2.65x | $-29.78 Million | $11.22 Million | ▼ -6.8% |
| 2019 | -2.49x | $-36.06 Million | $14.51 Million | ▼ -37.0% |
| 2018 | -1.81x | $-26.84 Million | $14.80 Million | ▲ +10.1% |
| 2017 | -2.02x | $-28.17 Million | $13.97 Million | ▼ -27.8% |
| 2016 | -1.58x | $-7.23 Million | $4.58 Million | ▲ +43.0% |
| 2015 | -2.77x | $-6.90 Million | $2.49 Million | ▼ -162.4% |
| 2014 | -1.05x | $-2.21 Million | $2.10 Million | ▼ -48.7% |
| 2013 | -0.71x | $-1.17 Million | $1.65 Million | ▼ -176.1% |
| 2012 | -0.26x | $-6.22 Million | $24.22 Million | — |